Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18650142 | METHODS OF TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY | April 2024 | February 2026 | Abandon | 22 | 1 | 1 | No | No |
| 18616227 | EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION | March 2024 | December 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18609857 | HYDROGELS AS CARRIERS OF ACTIVE INGREDIENTS AND METHODS OF PRODUCING THE SAME | March 2024 | December 2025 | Allow | 21 | 1 | 0 | No | No |
| 18569592 | SULFOXIMINE-CONTAINING ATR INHIBITOR COMPOUND | December 2023 | March 2026 | Allow | 27 | 0 | 0 | No | No |
| 18381849 | DEXTROMETHORPHAN TRANSDERMAL DELIVERY DEVICE | October 2023 | February 2026 | Allow | 28 | 3 | 0 | No | No |
| 18277701 | COMPOSITION FOR PREVENTING OR TREATING NERVOUS SYSTEM DISEASES COMPRISING COMPOUND THAT INHIBITS MTOR SIGNALING PATHWAY AS ACTIVE INGREDIENT | August 2023 | December 2025 | Allow | 28 | 0 | 0 | No | No |
| 18322693 | THERAPEUTIC AGENT NANOPARTICLES AND METHODS OF PREPARATION | May 2023 | December 2025 | Allow | 31 | 1 | 0 | No | No |
| 18311319 | USE OF CAVIAR EXTRACTS | May 2023 | March 2026 | Allow | 34 | 2 | 0 | Yes | No |
| 18140160 | SYNERGISTIC DISINFECTANT COMPOSITIONS HAVING ENHANCED ANTIMICROBIAL EFFICACY AND STABILITY, AND METHODS OF USING THE SAME | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18136589 | ALOE EXTRACTS FOR MICROBIAL NEUTRALISATION | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18136103 | TOPICAL COMPOSITIONS AND METHODS | April 2023 | January 2026 | Allow | 33 | 4 | 1 | No | No |
| 18032208 | SOLID STATE FORMS OF PRALSETINIB AND PROCESS FOR PREPARATION THEREOF | April 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18130583 | COMPOSITION FOR RELIEVING WOMAN MENOPAUSAL SYMPTOM COMPRISING A MIXED EXTRACT OF HOP AND CITRUS PEEL AND METHOD FOR TREATING OR ALLEVIATING MENOPAUSAL SYMPTOM USING THE SAME | April 2023 | January 2026 | Allow | 34 | 1 | 1 | Yes | No |
| 18025499 | CANNABIS PREVENTS NK INACTIVATION IN CANCER AND INCREASES NK FUNCTION | March 2023 | February 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18043864 | PHENOL DERIVATIVE | March 2023 | December 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 18114243 | Method For Extracting And Purifying Broad-Spectrum Cannabis Oil From Industry Hemp | February 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18108754 | COMPOSITION FOR PREVENTING OR AMELIORATING BROMHIDROSIS COMPRISING SEED FERMENTATION PRODUCT OF PLANT BELONGING TO THE GENUS LOTUS | February 2023 | February 2026 | Allow | 36 | 1 | 1 | No | No |
| 18041393 | METHOD AND COMPOUND FOR USE, IN TREATING AND/OR PREVENTING NETOSIS | February 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18040315 | MUCUS ADHESION DRUG DELIVERY | February 2023 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18009619 | NON-PORCINE FORMULATIONS AND METHODS THEREOF | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17825438 | COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND MORINGA PLANT COMPONENTS | May 2022 | February 2026 | Allow | 45 | 2 | 1 | Yes | No |
| 17559057 | RABEXIMOD IN THE TREATMENT OF RHEUMATOID ARTHRITIS | December 2021 | February 2026 | Abandon | 50 | 6 | 0 | No | No |
| 17543353 | ADJUVANTED NANOPARTICULATE INFLUENZA VACCINE | December 2021 | January 2026 | Abandon | 49 | 2 | 1 | No | Yes |
| 17276299 | WHITE PIGMENT FOR COSMETICS, AND COSMETIC | March 2021 | May 2023 | Abandon | 26 | 2 | 0 | No | No |
| 17271384 | METHOD FOR REDUCING PARASITE BURDEN IN A MOSQUITO | February 2021 | June 2024 | Allow | 39 | 4 | 0 | No | No |
| 17044769 | ORGANICALLY MODIFIED MINERAL MICRO-PARTICLES, METHODS OF PREPARING THE SAME AND USES THEREOF | October 2020 | November 2025 | Allow | 60 | 3 | 1 | No | No |
| 16769228 | INTRACRANIAL DRUG DELIVERY MATERIALS AND METHODS | June 2020 | August 2023 | Abandon | 39 | 3 | 1 | No | No |
| 16652768 | BI-LAYER PHARMACEUTICAL TABLET FORMULATION | April 2020 | January 2022 | Allow | 22 | 9 | 0 | Yes | Yes |
| 16807891 | Aza-Aryl 1H-Pyrazol-1-yl Benzene Sulfonamides | March 2020 | November 2021 | Abandon | 20 | 3 | 0 | Yes | No |
| 16636678 | COMPOSITION CONTAINING QUATERNARY AMMONIUM COMPOUND, ESPECIALLY FOR PRODUCING CARE AND CLEANING FORMULATIONS | February 2020 | November 2025 | Abandon | 60 | 8 | 1 | No | No |
| 16618011 | Bubblyte | November 2019 | May 2021 | Abandon | 17 | 1 | 1 | No | No |
| 16548866 | EYELINER PRODUCT AND METHOD THEREOF | August 2019 | August 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16459126 | AGRICULTURAL ADJUVANT COMPOSITIONS, PESTICIDE COMPOSITIONS, AND METHODS FOR USING SUCH COMPOSITIONS | July 2019 | October 2021 | Allow | 27 | 0 | 0 | Yes | No |
| 16228085 | FOAM CONTAINING UNIQUE OIL GLOBULES | December 2018 | November 2020 | Abandon | 23 | 1 | 1 | No | No |
| 16202851 | COMBINATION THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS | November 2018 | June 2023 | Abandon | 55 | 5 | 1 | No | No |
| 16131531 | SILICA FIBER COMPOSITIONS AND METHODS OF USE | September 2018 | April 2023 | Abandon | 55 | 4 | 1 | Yes | No |
| 16126608 | INTRASITE ADMINISTRATION AND DOSING METHODS AND PHARMACEUTICALS FOR USE THEREIN | September 2018 | April 2022 | Abandon | 43 | 1 | 1 | No | No |
| 15936749 | Cancer Diagnostic Metastasis Panel | March 2018 | November 2021 | Abandon | 44 | 2 | 0 | No | No |
| 15857555 | TREATING FUNGAL INFECTION OF THE NAIL UNIT | December 2017 | August 2018 | Abandon | 7 | 1 | 0 | No | No |
| 15833081 | WOUND DRESSING AND METHOD FOR REMOVING THE SAME | December 2017 | August 2020 | Abandon | 32 | 0 | 1 | No | No |
| 15811707 | HAIR CLEANSING CONDITIONER | November 2017 | September 2020 | Abandon | 34 | 4 | 1 | No | No |
| 15725226 | NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA | October 2017 | May 2018 | Abandon | 7 | 1 | 0 | No | No |
| 15671391 | METHODS AND SYSTEMS FOR PREPARING COMPOSITIONS | August 2017 | April 2022 | Abandon | 56 | 5 | 1 | No | No |
| 15609253 | TOPICAL COMPOSITIONS COMPRISING HYDROXY ACIDS AND CANNABINOIDS FOR SKIN CARE | May 2017 | October 2020 | Abandon | 40 | 2 | 1 | Yes | Yes |
| 15482166 | METHOD FOR THE SIMULTANEOUS PERMANENT SHAPING AND DYEING OF KERATINIC FIBERS | April 2017 | September 2018 | Abandon | 18 | 2 | 0 | No | No |
| 15443122 | THREE-PHASE CONTROLLED-RELEASE TABLET COMPRISING MELATONIN AND PROCESS OF PREPARATION | February 2017 | August 2018 | Abandon | 17 | 2 | 0 | No | No |
| 15408924 | Topical Avermectin Formulations and Methods For Elimination and Prophylaxis of Susceptible and Treatment Resistant Strains of Head Lice | January 2017 | January 2021 | Abandon | 48 | 3 | 1 | No | Yes |
| 15379371 | Pharmaceutical Compositions for Colon-Specific Delivery | December 2016 | July 2018 | Abandon | 19 | 2 | 0 | No | No |
| 15370528 | METHODS OF INHIBITING, PROTECTING AGAINST, OR TREATING UVR-INDUCED SKIN DAMAGE | December 2016 | May 2018 | Abandon | 17 | 2 | 1 | Yes | No |
| 15369701 | LIBRARY OF PH RESPONSIVE POLYMERS AND NANOPROBES THEREOF | December 2016 | May 2018 | Allow | 48 | 2 | 1 | Yes | No |
| 15353932 | COMPOSITIONS CONTAINING AS THE ACTIVE INGREDIENT COMPONENTS FROM SALVIA SCLAREA SEED | November 2016 | July 2018 | Abandon | 19 | 3 | 1 | No | No |
| 15337251 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY | October 2016 | October 2018 | Abandon | 24 | 2 | 1 | No | No |
| 15305949 | ACTIVE INGREDIENT (I) CONTAINING COMPOSITION AND METHOD FOR PREPARING SAME | October 2016 | June 2018 | Abandon | 20 | 2 | 0 | No | No |
| 15259105 | HEPMC | September 2016 | September 2018 | Abandon | 25 | 1 | 1 | No | No |
| 15259610 | METHOD AND COMPOUND FOR OPENING POTASSIUM CHANNELS OF MAMMAL VASCULAR SMOOTH MUSCLES IN A REMOTE CONTROL MANNER | September 2016 | August 2018 | Abandon | 23 | 2 | 1 | No | No |
| 15256751 | SURFACE MODIFICATION METHOD AND STRUCTURE FOR IMPROVING HEMOCOMPATIBILITY OF BIOMEDICAL METALLIC SUBSTRATES | September 2016 | October 2018 | Abandon | 25 | 2 | 1 | No | No |
| 15033471 | LIPID COMPOSITION FOR IMPROVING BODY COMPOSITION DURING CATCH-UP GROWTH | April 2016 | August 2020 | Abandon | 51 | 6 | 0 | No | No |
| 15021348 | HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS | March 2016 | September 2021 | Abandon | 60 | 6 | 0 | No | Yes |
| 14858388 | VEHICLE COMPOSITIONS ESSENTIALLY FREE OF PHARMACEUTICALLY ACTIVE AGENTS FOR THE IMPROVED TREATMENT OF ACNE AND RELATED DISORDERS | September 2015 | May 2018 | Abandon | 32 | 1 | 1 | No | No |
| 14828837 | METHOD OF USING PEELABLE FILM-FORMING COMPOSITION | August 2015 | November 2018 | Abandon | 51 | 2 | 1 | No | No |
| 14649614 | COSMETIC COMPOSITION COMPRISING CELLULOSE FIBERS WITH SMALL FIBER DIAMETER AND COMPARATIVELY SMALL ASPECT RATIO | June 2015 | May 2018 | Allow | 35 | 4 | 0 | Yes | No |
| 14572664 | TOPICAL AVERMECTIN FORMULATIONS AND METHODS FOR ELIMINATION AND PROPHYLAXIS OF SUSCEPTIBLE AND TREATMENT RESISTANT STRAINS OF HEAD LICE | December 2014 | September 2020 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 14383010 | SUNSCREEN COMPOSITION | September 2014 | October 2020 | Allow | 60 | 6 | 0 | Yes | Yes |
| 14218055 | PHOTOPROTECTIVE COMPOSITION CONTAINING AN UNMODIFIED GELLING STARCH AND POLYAMIDE PARTICLES | March 2014 | January 2024 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 14188496 | Method and Formulation for Chemical Peeling | February 2014 | August 2018 | Abandon | 54 | 3 | 0 | No | No |
| 14162808 | NANO SILVER-ZINC OXIDE COMPOSITION | January 2014 | September 2014 | Allow | 8 | 1 | 0 | No | No |
| 14161614 | ELECTROSPUN THERAPEUTIC CARRIER AND IMPLANT | January 2014 | October 2019 | Allow | 60 | 4 | 1 | Yes | Yes |
| 14152867 | Implantable Device Having a Coating with a Triblock Copolymer | January 2014 | July 2014 | Allow | 6 | 1 | 0 | No | No |
| 14107091 | REMOVING TYPE AQUEOUS MANICURE COMPOSITION | December 2013 | July 2018 | Abandon | 55 | 2 | 0 | No | Yes |
| 14075443 | Nanostructures for Drug Delivery | November 2013 | July 2014 | Allow | 8 | 0 | 0 | No | No |
| 13982635 | Composition containing a polyorganosiloxane, a larvicide, and an organic solvent | July 2013 | July 2018 | Abandon | 59 | 4 | 1 | Yes | No |
| 13935025 | MULTIPLE DRUG DELIVERY FROM A BALLOON AND PROSTHESIS | July 2013 | September 2014 | Allow | 15 | 1 | 0 | Yes | No |
| 13933944 | Stiffening Assembly | July 2013 | September 2014 | Allow | 15 | 1 | 0 | No | No |
| 13891225 | Drug Depots Having Different Release Profiles for Reducing, Preventing or Treating Pain and Inflammation | May 2013 | October 2014 | Allow | 17 | 2 | 0 | Yes | No |
| 13879990 | PROCESS FOR MAKING MULTIPARTICULATE GASTRORETENTIVE DOSAGE FORMS | April 2013 | September 2018 | Abandon | 60 | 7 | 1 | Yes | No |
| 13857511 | USE OF WF10 FOR TREATING ALLERGIC ASTHMA, ALLERGIC RHINITIS AND ATOPIC DERMATITIS | April 2013 | August 2014 | Allow | 16 | 1 | 0 | No | No |
| 13805981 | Disinfectant Composition | March 2013 | January 2019 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 13831268 | AEROSOL DELIVERY SYSTEMS, COMPOSITIONS AND METHODS | March 2013 | September 2014 | Allow | 18 | 1 | 0 | Yes | No |
| 13704814 | PULLULAN-CONTAINING POWDER, METHOD FOR PRODUCING THE SAME AND USE THEREOF | March 2013 | January 2017 | Abandon | 58 | 7 | 0 | Yes | No |
| 13772091 | SUSPENDING MEDIUM FOR GLITTER OR PIGMENTS IN URETHANE (METH)ACRYLATES | February 2013 | November 2018 | Abandon | 60 | 8 | 0 | Yes | Yes |
| 13711001 | COMPOSITION AND METHOD FOR DENTAL REMINERALIZATION | December 2012 | July 2018 | Abandon | 60 | 4 | 1 | No | Yes |
| 13634176 | COMPOSITION COMPRISING A DIBENZOYLMETHANE SCREENING AGENT AND A MEROCYANINE DICYANO OR CYANOACETATE DERIVATIVE; METHOD FOR THE PHOTOSTABILIZATION OF THE DIBENZOYLMETHANE SCREENING AGENT | November 2012 | October 2014 | Allow | 25 | 1 | 1 | Yes | No |
| 13603984 | SOLID DOSAGE FORMS COMPRISING AN ENTERIC COATING WITH ACCELERATED DRUG RELEASE | September 2012 | September 2019 | Allow | 60 | 6 | 0 | Yes | Yes |
| 13577711 | COMPOSITION FOR CLEANING TEETH COMPRISING NATURAL GLASS AND RELATED METHODS | August 2012 | May 2018 | Abandon | 60 | 8 | 0 | No | No |
| 13532023 | PHARMACEUTICAL COMPOSITIONS FOR PARENTERAL ADMINISTRATION | June 2012 | July 2014 | Allow | 24 | 2 | 1 | Yes | No |
| 13340405 | POLYMERIC STRUCTURES FOR ADSORBING BIOLOGICAL MATERIAL AND THEIR METHOD OF PREPARATION | December 2011 | August 2020 | Allow | 60 | 7 | 1 | Yes | Yes |
| 13043021 | Multi-layered Device | March 2011 | October 2020 | Allow | 60 | 6 | 2 | Yes | Yes |
| 12988211 | COSMETIC COMPOSITIONS COMPRISING EXOPOLYSACCHARIDES DERIVED FROM MICROBIAL MATS, AND USE THEREOF | March 2011 | May 2018 | Abandon | 60 | 6 | 1 | No | No |
| 12933231 | PREPARATIONS FOR REDUCING ITCHING AND OTHER PARAESTHESIAS WITH (1R,2S,5R)-2-ISOPROPYL-5-METHYL-N-(2-(PYRIDIN-2-YL)ETHYLCYCLOHEXANECARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-(CYANOMETHYL)-PHENYL)-2-ISOPROPYL-5-METHYLCYCLOHEXANECARBOXAMIDE AND/OR (1R,2S,5R)-N-(4-(CYANOMETHYL)-PHENYL)-2ISOPROPYL-5-METHYLCYCLOHEXANECARBOXAMIDE | December 2010 | July 2023 | Abandon | 60 | 6 | 0 | No | Yes |
| 12851154 | Antiseptic Liquid Formulation, A Method for Its Use, and A Method for Preparing the Formulation | August 2010 | March 2013 | Abandon | 31 | 1 | 1 | No | No |
| 12780905 | TOPICAL DRUG FOR TREATMENT AND/OR PREVENTION OF DIABETIC NEUROPATHY, MICROANGIOPATHY AND DIABETIC AND NON DIABETIC ULCERS AND WOUND INFECTION | May 2010 | October 2013 | Abandon | 41 | 5 | 1 | Yes | No |
| 12643546 | ELASTIC IMPLANTABLE COMPOSITES AND IMPLANTS COMPRISING SAME | December 2009 | February 2014 | Allow | 50 | 3 | 0 | No | No |
| 11912085 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF KIDNEY DISEASE | June 2008 | October 2015 | Allow | 60 | 2 | 1 | No | Yes |
| 12130614 | MEDICAL DEVICES INCORPORATING COLLAGEN INHIBITORS | May 2008 | July 2014 | Allow | 60 | 4 | 1 | No | No |
| 11948335 | UROLOGIC DEVICES INCORPORATING COLLAGEN INHIBITORS | November 2007 | June 2014 | Allow | 60 | 7 | 1 | Yes | No |
| 10516904 | REDUCTION OF CROSS-LINKING GELATIN IN GELATIN CAPSULES | November 2007 | March 2014 | Allow | 60 | 5 | 1 | No | Yes |
| 11596419 | Method to Fight Against Insects Including the Use of Hydrocarbon Compounds | January 2007 | October 2014 | Abandon | 60 | 2 | 1 | No | No |
| 11099900 | HAIR RELAXER COMPOSITIONS UTILIZING BIOACTIVE GLASS | April 2005 | March 2010 | Allow | 59 | 3 | 1 | Yes | No |
| 10530098 | REDUCING PIGMENTS | April 2005 | December 2008 | Allow | 45 | 2 | 0 | No | No |
| 10909587 | HIGH ASPECT RATIO METAL PARTICLES AND METHODS FOR FORMING SAME | August 2004 | June 2009 | Allow | 58 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BARHAM, BETHANY P.
With a 23.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BARHAM, BETHANY P works in Art Unit 1611 and has examined 83 patent applications in our dataset. With an allowance rate of 39.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner BARHAM, BETHANY P's allowance rate of 39.8% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BARHAM, BETHANY P receive 3.36 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BARHAM, BETHANY P is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +29.0% benefit to allowance rate for applications examined by BARHAM, BETHANY P. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 6.1% of applications are subsequently allowed. This success rate is in the 3% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.4% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 22.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 27% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 41.4% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 41.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 74.2% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.6% of allowed cases (in the 82% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 18.2% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.